Reach out to us anytime by emailing [email protected] or calling 561-235-0100 , and our friendly support staff will walk you through your questions with clear, personalized answers
EMPA-REG OUTCOME (Empagliflozin Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients) was the first major trial published evaluating SGLT2-i use for reduction of MACE in patients with type 2 diabetes and known CVD on empagliflozin
NAD+ injections are not intended to diagnose, treat, cure, or prevent any disease
Here's what's happening: Tretinoin accelerates your skin's natural exfoliation process, increasing cell turnover and bringing underlying debris, oil, and bacteria to the surface more quickly than usual
A study into the use of semaglutide in obese PCOS patients found that even low doses reduced their body weight by up to 80%, despite not seeing results with other weight loss plans